Heather Gardner to Animals
This is a "connection" page, showing publications Heather Gardner has written about Animals.
Connection Strength
0.467
-
Megquier K, Turner-Maier J, Morrill K, Li X, Johnson J, Karlsson EK, London CA, Gardner HL. The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations. PLoS One. 2022; 17(9):e0274383.
Score: 0.057
-
Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 Dec; 20(4):817-824.
Score: 0.057
-
Gardner HL, Sivaprakasam K, Briones N, Zismann V, Perdigones N, Drenner K, Facista S, Richholt R, Liang W, Aldrich J, Trent JM, Shields PG, Robinson N, Johnson J, Lana S, Houghton P, Fenger J, Lorch G, Janeway KA, London CA, Hendricks WPD. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019; 2:266.
Score: 0.046
-
Gardner HL, Rippy SB, Bear MD, Cronin KL, Heeb H, Burr H, Cannon CM, Penmetsa KV, Viswanadha S, Vakkalanka S, London CA. Phase I/II evaluation of RV1001, a novel PI3Kd inhibitor, in spontaneous canine lymphoma. PLoS One. 2018; 13(4):e0195357.
Score: 0.042
-
Gardner HL, Fenger JM, London CA. Dogs as a Model for Cancer. Annu Rev Anim Biosci. 2016; 4:199-222.
Score: 0.036
-
Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res. 2015 Jun 11; 11:131.
Score: 0.035
-
van der Heiden AD, Pensch R, Agger S, Gardner HL, Hendricks W, Zismann V, Wong S, Briones N, Turner B, Forsberg-Nilsson K, London C, Lindblad-Toh K, Arendt ML. Characterization of the genomic landscape of canine diffuse large B-cell lymphoma reveals recurrent H3K27M mutations linked to progression-free survival. Sci Rep. 2025 Feb 08; 15(1):4724.
Score: 0.017
-
McLinden GP, Avery AC, Gardner HL, Hughes K, Rodday AM, Liang K, London CA. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. J Vet Intern Med. 2024 May-Jun; 38(3):1666-1674.
Score: 0.016
-
London CA, Gardner H, Zhao S, Knapp DW, Utturkar SM, Duval DL, Chambers MR, Ostrander E, Trent JM, Kuffel G. Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology. Vet Comp Oncol. 2023 Dec; 21(4):565-577.
Score: 0.015
-
Dittrich K, Yildiz-Altay ?, Qutab F, Kwong DA, Rao Z, Nievez-Lozano SA, Gardner HL, Richmond JM, London CA. Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma. PLoS One. 2023; 18(8):e0290428.
Score: 0.015
-
Somarelli JA, Boddy AM, Gardner HL, DeWitt SB, Tuohy J, Megquier K, Sheth MU, Hsu SD, Thorne JL, London CA, Eward WC. Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. Mol Biol Evol. 2020 Jan 01; 37(1):11-17.
Score: 0.012
-
Barrett LE, Gardner HL, Barber LG, Sadowski A, London CA. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. BMC Vet Res. 2019 Aug 13; 15(1):291.
Score: 0.012
-
London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clin Cancer Res. 2018 12 15; 24(24):6396-6407.
Score: 0.011
-
Sadowski AR, Gardner HL, Borgatti A, Wilson H, Vail DM, Lachowicz J, Manley C, Turner A, Klein MK, Waite A, Sahora A, London CA. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res. 2018 Aug 24; 14(1):250.
Score: 0.011
-
Schuh EM, Portela R, Gardner HL, Schoen C, London CA. Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res. 2017 Oct 02; 13(1):294.
Score: 0.010
-
Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
Score: 0.010
-
Rippy SB, Gardner HL, Nguyen SM, Warry EE, Portela RA, Drost WT, Hostnik ET, Green EM, Chew DJ, Peng J, London CA. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Vet Res. 2016 Nov 17; 12(1):257.
Score: 0.010
-
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clin Cancer Res. 2017 May 15; 23(10):2565-2574.
Score: 0.010
-
Randall VD, Boston SE, Gardner HL, Griffin L, Oblak ML, Kubicek L. Pubectomy and stereotactic radiotherapy for the treatment of a non-resectable sacral osteosarcoma causing pelvic canal obstruction in a dog. Can Vet J. 2016 Sep; 57(9):945-9.
Score: 0.009
-
Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H. ?Np63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget. 2016 Jul 26; 7(30):48533-48546.
Score: 0.009
-
Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS One. 2016; 11(7):e0159607.
Score: 0.009
-
Karrasch NM, Lerche P, Aarnes TK, Gardner HL, London CA. The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. Can Vet J. 2015 Aug; 56(8):817-22.
Score: 0.009
-
London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS One. 2015; 10(4):e0124889.
Score: 0.009